Zimmer Biomet‘s ROSA Knee Robotics system Receives FDA Clearance for New Indications, Expanding Surgical Capabilities
WARSAW, IN – November 22, 2025 – Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced today that the U.S. Food adn Drug Administration (FDA) has cleared its ROSA Knee robotics system for additional surgical indications, potentially marking a significant advancement in knee replacement procedures. The expanded clearance allows surgeons to utilize ROSA Knee in a broader range of patient anatomies and surgical approaches.
the ROSA Knee system, launched in 2019, utilizes robotic technology to assist surgeons in performing partial and total knee replacements with greater precision.This latest FDA clearance builds upon previous approvals and reflects Zimmer Biomet’s ongoing investment in robotic-assisted surgery.
According to zimmer Biomet, the expanded indications will enable surgeons to address more complex knee deformities and personalize surgical plans to a greater degree. The company highlights that ROSA Knee’s technology provides real-time data and visualization during surgery, potentially leading to improved implant alignment, reduced soft tissue damage, and faster patient recovery times.
Fair value estimates from the Simply wall St Community currently range from US$95 to US$165, with some analysts suggesting the stock could be worth as much as 79% more than its current price. However, the wide range of opinions underscores the importance of considering regulatory and legal risks when evaluating the company.
Zimmer Biomet has no position in any stocks mentioned and provides commentary based on historical data and analyst forecasts using an unbiased methodology. The company emphasizes that its analysis is not financial advice and does not account for individual investment objectives or financial situations.
